AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21999138
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly two-needle arthrocenteses plus low molecular weight HA (E)
Trial: 21999138
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly single-needle arthrocenteses plus low molecular weight HA (F)
Trial: 18388888
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise (treatment group)
Trial: 15538395
Drug: Alprostadil transdermal
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered by self-insertion into the glans meatus.
Trial: 15538395
Drug: Alprostadil transdermal
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered dropwise into the metal opening without touching the penis.
Trial: 12874157
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Chlorella-derived dietary supplement
Trial: 12874157
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Chlorella-derived dietary supplement
Trial: 10563544
Drug: Nicotine solution
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine solution (1.2 mg, pH 4.5)
Trial: 1681215
Drug: Ocular tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ocular tetracycline treatment
Trial: 6496995
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (5.0 mg)
Trial: 6496995
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.05-0.07 mg/kg)
Trial: 6496995
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine and Intravenous morphine
Trial: 24487957
Drug: High-intensity laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity laser therapy (HILT) + exercise
Trial: 24487957
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) + exercise
Trial: 22065170
Drug: Tovaxin (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tovaxin (autologous T-cell immunotherapy)
Trial: 12850395
Drug: lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine 10 to 20 mg
Trial: 12850395
Drug: nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine GITS 30 to 60 mg
Trial: 10593371
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of ganirelix administered subcutaneously
Trial: 10593371
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of ganirelix administered intravenously
Trial: 6809161
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine chewing-gum
Trial: 6809161
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mg nicotine, unbuffered)
Trial: 28931384
Drug: Internet-based tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based tool for parents (monthly emails with links to an age-appropriate website)
Trial: 26037730
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list group (no acupuncture treatment)
Trial: 23833851
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg) added to bupivacaine (0.5%) - fentanyl (50 microg)
Trial: 19961932
Drug: Proguanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil with efavirenz (400mg daily for 11 days)
Trial: 19213336
Drug: Kuntai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsule (KTC) 4 capsules twice a day for 1 year
Trial: 19213336
Drug: Premarin 0.45
RxNorm normalized name: Premarin 0.45mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 0.45 mg per day (with 2 mg medroxyprogesterone for Ue) for 1 year
Trial: 19213336
Drug: Kuntai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsule (KTC)
Trial: 10812283
Drug: Daily buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buprenorphine administration (8 mg)
Trial: 10812283
Drug: Thrice-weekly buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly buprenorphine administration (16 mg on Mondays and Wednesdays, 24 mg on Fridays)
Trial: 6809024
Drug: Pirprofen 200
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen 200 mg 8 hourly
Trial: 29384321
Drug: Astaxanthin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (8 mg once daily for 8 weeks)
Trial: 26922656
Drug: AZD8529 40
RxNorm normalized name: AZD8529
DrugBank: AZD8529 (DB16073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8529 40 mg
Trial: 21076372
Drug: Valganciclovir prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir prophylaxis (900 mg once daily for 200 days)
Trial: 21076372
Drug: Valganciclovir prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir prophylaxis (900 mg once daily for 100 days)
Trial: 16120821
Drug: 32 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg/d candesartan
Trial: 19211712
Drug: 64 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64 mg/d candesartan
Trial: 11865366
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous antithrombin III
Trial: 10599402
Drug: Normovolemic haemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolemic haemodilution with crystalloid solutions until a hematocrit value of 21%
Trial: 492050
Drug: Metoprolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.2 mg/kg)
Trial: 27697423
Drug: Sticker prompts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sticker prompts affixed to refuse bins in treatment group
Trial: 21359979
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection (1/100,000) in the control group
Trial: 21359979
Drug: No epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No epinephrine injection in the intervention group
Trial: 18232619
Drug: Self-efficacy for
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Trial: 15533488
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (15% fat or less) with supplements (vitamin E and selenium)
Trial: 15533488
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet (15% fat or less) without supplements
Trial: 15533488
Drug: Supplements alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements alone (vitamin E and selenium)
Trial: 9659838
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C (ephedrine 20 mg and caffeine 200 mg)
Trial: 8719299
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy for 3 months
Trial: 8719299
Drug: GHRH combined
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH combined with pyridostigmine (PD, 120 mg po)
Trial: 8719299
Drug: PD administration
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD administration
Trial: 31279972
Drug: PVI +
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVI + VOM ethanol infusion
Trial: 28410341
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Trial: 22350036
Drug: Xanthan-based 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthan-based 1.5% chlorhexidine (CHX) gel (Xan-CHX)
Trial: 19116968
Drug: Disodium EDTA
RxNorm normalized name: Disodium EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium EDTA administration through single needle mesotherapy and 15 minutes of pulsed-mode 1 MHz-ultrasound
Trial: 19116968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no disodium EDTA treatment)
Trial: 19116968
Drug: Disodium EDTA
RxNorm normalized name: Disodium EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium EDTA administration
Trial: 12692182
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg day-1 for 8 weeks)
Trial: 2058825
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and alfentanil (ED95)
Trial: 2058825
Drug: Meperidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (25 mg i.v.) given to 5 patients from K1
Trial: 4082090
Drug: Aspirin 50
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 50 mg/day
Trial: 4082090
Drug: Aspirin 324
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 324 mg/day
Trial: 30500136
Drug: Plant-based hypoallergenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-based hypoallergenic ointment (Doctor Rogers RESTORE® Healing Balm)
Trial: 30500136
Drug: Petroleum-based lanolin-containing
RxNorm normalized name: lanolin / petrolatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petroleum-based lanolin-containing ointment (Aquaphor® Healing Ointment)
Trial: 25850997
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily
Trial: 15773645
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of local anaesthetic and steroid
Trial: 12913719
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg selenium daily orally for 1 month
Trial: 10498759
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) capsules (2 g b.d.; containing 1.4 g eicosapentaenoic acid and 1.0 g docosahexaenoic acid per day)
Trial: 10498759
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil capsules (2 g b.d.; placebo group)
Trial: 10498759
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplements (self-reported use)
Trial: 8604261
Drug: Bupivacaine-norepinephrine topical
RxNorm normalized name: mepivacaine / norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-norepinephrine topical solution (Bupivanor)
Trial: 8604261
Drug: Topical tetracaine-adrenaline-cocaine
RxNorm normalized name: adrenalone / tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine-adrenaline-cocaine (TAC)
Trial: 15050319
Drug: Hyperfractionated accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated accelerated radiochemotherapy (to 70.6 Gy) with concurrent mitomycin C and 5-fluorouracil
Trial: 15050319
Drug: Hyperfractionated accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated accelerated radiotherapy (RT) alone (to a total radiation dose of 77.6 Gy)
Trial: 15448032
Drug: Bevacizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (3 or 10 mg/kg every 2 weeks)
Trial: 15448032
Drug: Bevacizumab (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (higher dose)
Trial: 15448032
Drug: Bevacizumab (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (long-term therapy)
Trial: 8557014
Drug: alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 20 micrograms kg‐1 and propofol 2.0‐2.5 mg kg‐1
Trial: 8557014
Drug: fentanyl 3
RxNorm normalized name: FENTANYL 37.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 3 micrograms kg‐1 and thiopentone 4‐6 mg kg‐1
Trial: 1660414
Drug: Methylprednisolone treatment
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone treatment in steroid‐treated control group (n = 10)
Trial: 6627819
Drug: metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (100 to 400 mg/day) with prazosin (2 to 4 mg/day)
Trial: 6627819
Drug: labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (200 to 1000 mg/day)
Trial: 31728883
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles.
Trial: 22770926
Drug: Silymarin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (three 140‐mg tablets daily for 3 months)
Trial: 22770926
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets daily for 3 months)
Trial: 20398339
Drug: Intramuscular artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily)
Trial: 20398339
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (3.6 mg/kg immediately followed by 1.8 mg/kg daily)
Trial: 17512087
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1)
Trial: 17512087
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1) and another course for remaining lesions
Trial: 18242155
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg i.v.
Trial: 7653830
Drug: droperidol 2.5
RxNorm normalized name: droperidol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 2.5 mg i.v.
Trial: 2720018
Drug: Treatment (Diazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (Diazepam, Alprazolam)
Trial: 789024
Drug: Th1165a (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1165a (5 mg)
Trial: 789024
Drug: Th1165a (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1165a (10 mg)
Trial: 789024
Drug: Th1165a (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1165a (15 mg)
Trial: 789024
Drug: Th1165a (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Th1165a (20 mg)
Trial: 789024
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate (20 mg)
Trial: 30556110
Drug: Acalabrutinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 15 mg
Trial: 30556110
Drug: Acalabrutinib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 400 mg
Trial: 30556110
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg
Trial: 25155034
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg on demand (PRN)
Trial: 23827533
Drug: Manualised Individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manualised Individual Cognitive Behaviour Treatment (M‐iCBT)
Trial: 21272272
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) for up to 6 months
Trial: 10767671
Drug: Active capsules
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active capsules containing 160 mg of bilberry extract (25-percent anthocyanosides) taken three times daily for 21 days
Trial: 10767671
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules containing only inactive ingredients taken three times daily for 21 days
Trial: 9496202
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg orally, given daily for 5 days before operation
Trial: 3332506
Drug: Mefloquine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (250 mg) and sulfadoxine‐pyrimethamine once a week
Trial: 3332506
Drug: Sulfadoxine‐pyrimethamine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (two tablets) once a week
Trial: 3332506
Drug: Sulfadoxine‐pyrimethamine (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (one tablet containing sulfadoxine 500 mg and pyrimethamine 25 mg) twice a week
Trial: 27703984
Drug: Advantix (permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advantix (permethrin and imidacloprid combination)
Trial: 23870287
Drug: C.E.R.A. (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. (any administration interval)
Trial: 23870287
Drug: Shortening administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shortening administration interval (Q2W)
Trial: 19276275
Drug: Molecularly targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly targeted agents
Trial: 11413177
Drug: Intravenous nitrates
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitrates
Trial: 11413177
Drug: Heparin, aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin, aspirin, beta blockers, intravenous nitrates
Trial: 11413177
Drug: Aspirin, aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, aspirin and heparin, coronary angiography
Trial: 9163261
Drug: Ketoprofen 2
RxNorm normalized name: ketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 2 mg/kg body weight i.v. 20 min before surgery
Trial: 28881462
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W) or every 2 weeks (Q2W) after an initial 160 mg dose
Trial: 28881462
Drug: Etanercept (ETN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (ETN; 50 mg twice weekly)
Trial: 26742907
Drug: Caffeine (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (65 mg/cup espresso)
Trial: 18482245
Drug: Propofol (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3.5 mg.kg(‐1))
Trial: 18482245
Drug: Propofol-Ketamine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-Ketamine (2.5 mg.kg(‐1))
Trial: 18482245
Drug: Propofol-Midazolam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-Midazolam (2.5 mg.kg(‐1))
Trial: 12926840
Drug: Reflexology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatment (manual pressure on specific points in the feet and massage of the calf area)
Trial: 4064532
Drug: Glucagon (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (0.5 mg)
Trial: 19378542
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg)
Trial: 26813451
Drug: Acetazolamide (ACET)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACET) 500 mg for two consecutive days
Trial: 24716739
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg per day for two days)
Trial: 24716739
Drug: Pamidronate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate and Placebo (both groups receive paracetamol)
Trial: 15981758
Drug: RUTF supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUTF supplement